Abzena provides a suite of complementary services and technologies to R&D organisations to improve the chances of successful development of therapeutic proteins and antibodies, it is therefore poised to capitalise on the growth of the biopharmaceutical market. The Group has significant know-how, supported by a broad patent estate, to enable it to create better biopharmaceuticals for its customers.

Abzena operates a balanced business model with growing revenues from its service business and the potential for significant future growth through royalty bearing licences for the application of its technologies to biopharmaceutical products. The Group’s technologies and services are provided through its wholly-owned subsidiaries, PolyTherics and Antitope.

Horizon has been ranked as one of the fastest growing biotechnology companies in Europe by Deloitte with staff of more than 200 people spread across R&D, operations and commercial functions and accommodated within a 80,000 sq. ft. of state-of-the-art facilities in Cambridge, MA, USA. The company has grown rapidly and now has a customer base approaching 1,000 organisations including major pharmaceutical, biotech and diagnostic companies as well as leading academic research centres. Horizon was named the 2014 European Mediscience Emerging Star Award following its £68.6 million IPO on the AIM market of the LSE and an all-time record for a Life Science company.

With a network of almost 200 offices, Martin & Co is one of the largest franchised property businesses in the UK. Established in 1986, it provides a responsive local letting and sales service with the backing of a national brand.The company has a strong focus on lettings and currently manages 30,000 properties on behalf of private clients, which amounts to a town the size of Maidenhead in Berkshire. In March 2012, Martin & Co introduced an estate agency service with a view to leverage and extend its established brand name in the UK. The company's approach to estate agency differs from standard commission based estate agent sales models, in that it offers an option for vendors to instruct it on a pay-as-you-go basis, depending on which services they require.

Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. It is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.